ADQ Launches Holding Company Arcera To Build A Global Life Sciences Powerhouse Anchored In Abu Dhabi

In a significant move within the life sciences sector, ADQ, based in Abu Dhabi, has unveiled the formation of Arcera, a new global holding company with its headquarters in the UAE. Arcera emerges with a mission to tackle healthcare challenges by delivering products aimed at enhancing human health and extending life expectancy. This initiative not only consolidates ADQ’s existing assets in the life sciences field but also marks a strategic step towards fulfilling Abu Dhabi’s 2030 Healthcare Life Sciences Vision and positioning the UAE as a leading hub in science and technology.

Arcera's foundation is strengthened by incorporating ADQ’s shareholdings from three pivotal companies: Acino International, Birgi Mefar Group (BMG), and Amoun Pharmaceutical Company. Acino, with its rich history dating back to 1836, is renowned for its international distribution of a broad spectrum of medicines. BMG stands out in Türkiye for its sterile production services, while Amoun leads in Egypt as a pharmaceutical manufacturer. Together, these entities bring over 6,500 employees under Arcera’s banner, with operations spanning more than 90 countries across four continents.

The company boasts an impressive portfolio of 2,000 branded medicines covering various therapeutic areas such as neurology, gastroenterology, and cardiovascular diseases. With manufacturing and packaging facilities located in seven countries including the UAE, Switzerland, and Egypt, Arcera is poised for significant growth. The company aims to double its revenue over the next five years through strategic acquisitions and partnerships globally.

At the forefront of Arcera’s ambitious agenda is Isabel Afonso, appointed as Chief Executive Officer. Afonso brings to the table over two decades of leadership experience in the pharmaceutical industry, complemented by her roles in MedTech and other sectors. Under her guidance, Arcera is set to navigate its global expansion and transformation efforts.

Hamad Al Hammadi, Deputy Chief Executive Officer of ADQ, highlighted Arcera’s strategic importance in unlocking portfolio value and driving innovation. He emphasized Arcera's role in contributing significantly to Abu Dhabi's life sciences sector and improving patient outcomes through innovative solutions.

Afonso expressed her commitment to leading Arcera towards becoming a global leader in the life sciences industry. She underscored the importance of high-quality medicines and Arcera’s role in accelerating growth plans for its businesses. The company's name, combining 'arc' and 'era,' symbolizes its vision for upward momentum and longevity in the healthcare sector.

Arcera's establishment reflects a significant leap forward for Abu Dhabi's aspirations in healthcare and technology. By leveraging advanced technologies and fostering an environment conducive to innovation, Arcera aims to address the growing demand for effective healthcare solutions. Its focus on nurturing talent and driving organic growth through strategic acquisitions positions it as a key player on the global stage of life sciences.

With inputs from WAM